Funds the move of SGB-9768 and other RNAi programs toward registration studies.
- Amount
- $110M
- Stage
- Series B
- Announced
- 9 December 2025
- Lead
- Invus
- Other investors
- Legend Capital, Vivo Capital, Sino Biopharm, SymBiosis, Lake Bleu Capital, Eli Lilly
- Use of funds
- Funds the move of SGB-9768 and other RNAi programs toward registration studies.
- Checked
- Amount and date checked against the press source